Concord Biotech acquires 100% in Celliimune Biotech for ₹66 lakh

Listed-company acquisitionStrategic Transactions View source PDF Explain this filing

CONCORDBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹1025.00

prior close

₹1010.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+1.1%-1.1% vs market

Pharmaceuticals peers, median of 158sector+0.6%-0.6% vs sector

On the reaction day the stock moved 1.1 pts less than Nifty Smallcap 250 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.1

10m

+0.7

15m

+0.3

30m

+0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0+1.1-1.1+0.6-0.6

Next day

+0.7+1.2-0.5+1.0-0.3

+2.4+5.2-2.7+3.7-1.3

+3.4+5.3-1.9+4.2-0.8

+3.5+7.0-3.5+5.7-2.2

+2.4+6.5-4.1+5.8-3.4

+1.4+10.0-8.7+8.5-7.1

15d

+5.8+13.6-7.8+10.4-4.6

+19.2+17.0+2.2+12.5+6.7

+16.5+13.7+2.7+12.8+3.7

+25.1+22.8+2.3+21.9+3.2

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 158Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Concord Biotech has acquired 100% stake in Celliimune Biotech Private Limited for ₹66 lakh in cash, completed on April 2, 2026. Celliimune is a biopharma startup (incorporated Jan 2025, nil turnover) focused on DNA engineering for cancer therapeutics and novel cell & gene therapy. The deal is a related party transaction as the promoter group previously held a majority stake in Celliimune; done at arm's length. This follows Concord's earlier intimation dated November 13, 2025.

Likely market impact

Small strategic move into cancer therapy R&D; related-party deal with promoter-linked entity; financial impact minimal given ₹66L size and target's zero revenue.